Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 plus Pembrolizumab in Advanced Biliary Tract Cancer
NCT06978114Phase 2Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jun 2025
- Primary completion
- May 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan in biliary tract cancer (BTC), sponsored by Biokin Pharmaceutical. Started Jun 2025; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06978114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06978114.